Abstract
To examine the appropriate treatment of oligo-terato-asthenozoospermic patients with metabolic syndrome, 45 patients were treated with metformin for 6 months. The use of metformin was associated with a statistically significant reduction in insulin resistance and sex hormone-binding globulin levels, a statistically significant increase in serum androgen levels, and a consequent improvement in semen characteristics.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
MeSH terms
-
Adult
-
Androgens / blood
-
Asthenozoospermia / blood
-
Asthenozoospermia / complications
-
Asthenozoospermia / drug therapy*
-
Humans
-
Hypoglycemic Agents / pharmacology
-
Infertility, Male / blood
-
Infertility, Male / complications
-
Infertility, Male / drug therapy
-
Insulin Resistance / physiology
-
Male
-
Metabolic Syndrome / blood
-
Metabolic Syndrome / complications
-
Metabolic Syndrome / drug therapy*
-
Metformin / pharmacology*
-
Oligospermia / blood
-
Oligospermia / complications
-
Oligospermia / drug therapy*
-
Semen / drug effects*
-
Semen / physiology
-
Semen Analysis
-
Sex Hormone-Binding Globulin / analysis
Substances
-
Androgens
-
Hypoglycemic Agents
-
Sex Hormone-Binding Globulin
-
Metformin